secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001193125-26-021229
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs
--------------------------------------------------------------------------------

- CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.
- FY2025 cash bonuses: CEO $487,740; CFO $218,708; CCO $201,588; SVP Reg $161,784.
- CEO granted 131,400 stock options and 114,200 RSUs; other NEOs received smaller awards.
- New Key Executive Change in Control/Severance Plan offers up to 24 months salary + 150% target bonus + full equity acceleration in change-in-control event.
- Outside a change-in-control, CEO gets 18 months salary, 100% target bonus, and 25% equity acceleration; other execs get 9-12 months with no equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526021229/0001193125-26-021229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526021229/d93569d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-021229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer